Roscovitine, a cyclin-dependent kinases (CDKs) inhibitor, has been reported to have anti-
tumor effects in some cancer cell lines by inducing apoptosis. However, the exact underlying …

Purine analogue roscovitine, a cyclin-dependent kinase (CDK) inhibitor, has shown strong
anti-proliferative and pro-apoptotic effects in solid and hematologic cancers such as non …

Chemical inhibitors of cyclin-dependent kinase (CDK), like roscovitine, are promising drugs
in the context of new cancer therapies. Roscovitine and related compounds, like seliciclib …

Inhibitors of cyclin‐dependent kinases (CDKs) undergoing clinical trials as anticancer
agents usually target several CDKs in cells. Some of them are also able to increase cellular …

Among the ten pharmacological inhibitors of cyclin-dependent kinases (CDKs) currently in
clinical trials, the purine roscovitine (CYC202, Seliciclib) is undergoing phase 2 trials against …

Exposure of human HeLaS3 cervix carcinoma cells to high doses of conventional cytostatic
drugs, eg cisplatin (CP) strongly inhibits their proliferation. However, most cytostatic agents …

Roscovitine, a purine analogue, has been considered for the treatment of cancer. Anti-
cancer therapeutic efficacy is being evaluated in clinical trials. However, the mechanisms …

The cell cycle is tightly regulated by the family of cyclin-dependent kinases (CDKs). CDKs
act as regulatory factors on serine and threonine residues by phosphorylating their …

The cyclin-dependent kinase (CDK) inhibitor roscovitine is under evaluation in clinical trials
for its antiproliferative properties. Roscovitine arrests cell cycle progression in G1 and in G2 …

Cyclin-dependent kinases (Cdks) play essential roles in the intracellular controls of the cell
cycles. Roscovitine,[2-(R)-(1-ethyl-2-hydroxyethylamino)-6-benzylamino-9-isopropylpurine] …